Related Experiment Videos
Structure-based design of immunologically active therapeutic peptides
1Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104-6082, USA. murali@xray.med.upenn.edu
Immunologic Research
|February 28, 1998
Summary
Therapeutic peptidomimetics mimic protein functions by engineering surface loops. This study developed novel peptidomimetics targeting CD4 and TNF receptors for therapeutic applications.
Area of Science:
- Biochemistry and Molecular Biology
- Immunology
- Drug Discovery
Background:
- Peptides mimic protein functions by adopting local structural features like secondary structure and charge distribution.
- Therapeutic peptidomimetics are engineered from surface loop structures of proteins and receptors for immunological relevance.
- Target molecules include immunoglobulin fold-containing proteins (e.g., antibodies, CD4 receptors) and cystine-knot-containing receptors (e.g., TNF, CD40).
Purpose of the Study:
- To engineer therapeutic peptidomimetics that interfere with the functions of specific target molecules.
- To utilize molecular recognition loops as templates for peptidomimetic design.
- To discuss the development of peptidomimetics targeting the CD4 receptor and the TNF receptor.
Main Methods:
- Engineering surface loop structures of proteins and receptors.
- Utilizing molecular recognition loops as templates for peptidomimetic development.
- Focusing on immunoglobulin fold-containing CD4 receptors and cystine-knot-containing TNF receptors as molecular targets.
Main Results:
- Development of peptidomimetics capable of mimicking protein functions.
- Successful engineering of surface loops for immunological relevance.
- Demonstrated interference with the functions of target molecules through designed peptidomimetics.
Conclusions:
- Peptidomimetics can be effectively designed to target and interfere with the functions of specific receptors.
- The strategy of using molecular recognition loops as templates is viable for developing therapeutic peptidomimetics.
- This approach holds promise for developing novel therapeutics against diseases involving CD4 and TNF pathways.